The association between perinatal factors and cardiometabolic risk factors in children and adolescents with overweight or obesity: A retrospective two-cohort study

PLoS Med. 2023 Jan 13;20(1):e1004165. doi: 10.1371/journal.pmed.1004165. eCollection 2023 Jan.

Abstract

Background: Children with obesity have an increased risk of cardiometabolic risk factors, but not all children carry a similar risk. Perinatal factors, i.e., gestational age (GA) and birth weight for GA, may affect the risk for metabolic complications. However, there are conflicting data whether the association between birth size and cardiometabolic risk factors is independent among children with obesity. Moreover, differential effects of GA and birth weight for GA on cardiometabolic risk factors in pediatric obesity are still unexplored. We aimed to investigate the association between birth weight for GA and cardiometabolic risk factors in children and adolescents with overweight or obesity and to assess whether the association is modified by prematurity.

Methods and findings: We conducted a retrospective study of 2 cohorts, using data from the world's 2 largest registers of pediatric obesity treatment-The Swedish childhood obesity treatment register (BORIS) and The Adiposity Patients Registry (APV) (1991 to 2020). Included were individuals with overweight or obesity between 2 to 18 years of age who had data of birth characteristics and cardiometabolic parameters. Birth data was collected as exposure variable and the first reported cardiometabolic parameters during pediatric obesity treatment as the main outcome. The median (Q1, Q3) age at the outcome measurement was 11.8 (9.4, 14.0) years. The main outcomes were hypertensive blood pressure (BP), impaired fasting glucose, elevated glycated hemoglobin (HbA1c), elevated total cholesterol, elevated low-density lipoprotein (LDL) cholesterol, elevated triglycerides, decreased high-density lipoprotein (HDL) cholesterol, and elevated transaminases. With logistic regression, we calculated the odds ratio (OR) and its 95% confidence interval (CI) for each cardiometabolic parameter. All the analyses were adjusted for sex, age, degree of obesity, migratory background, and register source. In total, 42,760 (51.9% females) individuals were included. Small for GA (SGA) was prevalent in 10.4%, appropriate for GA (AGA) in 72.4%, and large for GA (LGA) in 17.2%. Most individuals (92.5%) were born full-term, 7.5% were born preterm. Median (Q1, Q3) body mass index standard deviation score at follow-up was 2.74 (2.40, 3.11) units. Compared with AGA, children born SGA were more likely to have hypertensive BP (OR = 1.20 [95% CI 1.12 to 1.29], p < 0.001), elevated HbA1c (1.33 [1.06 to 1.66], p = 0.03), and elevated transaminases (1.21 [1.10 to 1.33], p < 0.001) as well as low HDL (1.19 [1.09 to 1.31], p < 0.001). On the contrary, individuals born LGA had lower odds for hypertensive BP (0.88 [0.83 to 0.94], p < 0.001), elevated HbA1c (0.81 [0.67 to 0.97], p < 0.001), and elevated transaminases (0.88 [0.81 to 0.94], p < 0.001). Preterm birth altered some of the associations between SGA and outcomes, e.g., by increasing the odds for hypertensive BP and by diminishing the odds for elevated transaminases. Potential selection bias due to occasionally missing data could not be excluded.

Conclusions: Among children and adolescents with overweight/obesity, individuals born SGA are more likely to possess cardiometabolic risk factors compared to their counterparts born AGA. Targeted screening and treatment of obesity-related comorbidities should therefore be considered in this high-risk group of individuals.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Birth Weight
  • Body Mass Index
  • Cardiometabolic Risk Factors*
  • Child
  • Cholesterol, HDL
  • Cohort Studies
  • Female
  • Glycated Hemoglobin
  • Humans
  • Hypercholesterolemia
  • Hypertension* / epidemiology
  • Hypertension* / etiology
  • Infant, Newborn
  • Male
  • Overweight* / complications
  • Overweight* / epidemiology
  • Pediatric Obesity* / complications
  • Pediatric Obesity* / epidemiology
  • Pregnancy
  • Premature Birth*
  • Retrospective Studies
  • Risk Factors
  • Transaminases

Substances

  • Cholesterol, HDL
  • Glycated Hemoglobin
  • Transaminases

Grants and funding

This work was supported by the SOPHIA consortium (875534 to RWH) http://imisophia.eu, the German Center for Diabetes research (DZD) (82DZD14E1G to RWH) https://www.dzd-ev.de/, Åke Wiberg’s foundation (M21-0129 to EH) https://ake-wiberg.se/, Magnus Bergvall’s foundation (2021-04261 to EH) www.magnbergvallsstiftelse.nu, Ollie & Elof Ericsson’s foundation (EH) https://www.oestiftelse.se/, Tore Nilsson’s foundation (2021-00896 to EH) https://www.torenilsonsstiftelse.nu/, Anna-Lisa & Arne Gustafsson’ foundation (EH and RRP) https://gustafssonstiftelsen.se/, the Solstickan foundation (RRP) www.solstickan.se, HRH Crown Princess Lovisa (2021-00623 to EH; 2022-00689 to RRP) www.kronprinsessanlovisa.se, The foundation of Sällskapet Barnavård (RRP) https://ki.se/kbh/sallskapet-barnavard-2022, the Freemason Foundation for Children’s Welfare (RRP and MN) https://frimurarorden.se/, the Swedish Heart and Lung Foundation (20210620 to CM) www.hjart-lungfonden.se, the and regional agreement on clinical research between Region Stockholm and Karolinska Institutet (ALF) (2020-0443 to MN) www.researchweb.org/is/en/stockholm. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.